AbbVie (ABBV) recently received U.S. FDA approval for a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn's disease, offering patients a home-based treatment option via an on-body injector. This regulatory milestone adds to the company's pipeline of product news and reinforces its strategic focus on expanding indications for its key franchise. Financially, AbbVie has demonstrated strong momentum with a 1-month share price return of 8.47% and a year-to-date return of 25.04%, supported by robust multi-year total shareholder returns. Management reports that the erosion of Humira revenue, approximately US$18 billion, has been effectively offset by roughly US$28 billion in growth from other platforms, with 2026 guidance projected to be nearly US$10 billion above pre-Humira peak levels. Valuation perspectives on AbbVie are mixed. While the stock trades slightly above the average analyst target and a specific fair value estimate of $284.79 suggests it is currently overvalued by about 1%, a discounted cash flow (DCF) model indicates substantial upside, valuing the shares at approximately $503.55 based on future cash flows. This divergence highlights a debate over whether the stock is expensive on current earnings or undervalued regarding long-term cash generation potential. Investors must weigh these positive growth signals against specific risks that could alter the company's narrative. Key concerns include potential pricing pressure from U.S. drug negotiations and the possibility that key oncology investments underperform expectations. These factors, alongside the mixed valuation signals, create a complex investment case requiring careful stress testing of underlying assumptions.